Search results
Showing 1111 to 1125 of 2581 results for methods
This quality standard covers assessing and managing hearing loss in adults (aged 18 and over). It includes people presenting with hearing loss for the first time in adulthood whether it started in adulthood or earlier. It describes high-quality care in priority areas for improvement.
View quality statements for QS185Show all sections
Sections for QS185
- Quality statements
- Quality statement 1: Earwax removal
- Quality statement 2: Sudden onset of hearing loss
- Quality statement 3: Rapid worsening of hearing loss
- Quality statement 4: Audiological assessment
- Quality statement 5: Provision of hearing aids
- Quality statement 6: Follow-up audiology appointment
- About this quality standard
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
This guideline covers antenatal care for all pregnant women with complex social factors (particularly alcohol or drug misuse, recent migrant or asylum seeker status, difficulty reading or speaking English, aged under 20, domestic abuse). It offers advice on improving access to care, maintaining contact with antenatal carers, and additional information and support for these women.
Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)
This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.
View quality statements for QS147Show all sections
Sections for QS147
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers. Your involvement is highly valued. We are guided by your knowledge and experience.
Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (HTG199)
Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.
View recommendations for HTG199Show all sections
Sections for HTG199
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.